Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib
- Author:
Sogawa RINTARO
1
;
Saita TETSUYA
;
Yamamoto YUTA
;
Kimura SAKIKO
;
Narisawa YUTAKA
;
Kimura SHINYA
;
Shin MASASHI
Author Information
1. Department of Pharmacy
- Keywords:
Afatinib;
Enzyme-linked immunosorbent assay;
Therapeutic drug monitoring;
Tyrosine-kinase inhibitor
- From:
Journal of Pharmaceutical Analysis
2019;9(1):49-54
- CountryChina
- Language:Chinese
-
Abstract:
Afatinib is an oral tyrosine kinase inhibitor (TKI) approved for treating advanced non-small cell lung cancer. It is necessary to develop a simple quantification method for TKIs in order to facilitate therapeutic drug monitoring (TDM) in clinical settings. This study sought to develop a simple and sensitive com-petitive enzyme-linked immunosorbent assay (ELISA) to quantify afatinib in plasma for routine phar-macokinetic applications. An anti-afatinib antibody was obtained using (S)-N-4-(3-chloro-4-fluor-ophenyl)-7-(tetrahydrofuran-3-yloxy)-quinazoline-4,6-diamine (CTQD), which has the same sub-structure as afatinib, as a hapten. Enzyme labeling of afatinib with horseradish peroxidase was similarly performed using CTQD. A simple competitive ELISA for afatinib was developed based on the principle of direct competition between afatinib and the enzyme marker for the anti-afatinib antibody, which had been immobilized on the plastic surface of a microtiter plate. Plasma afatinib concentrations below the limit of quantification of 30 pg/mL were reproducibly measurable. Also, the values of plasma afatinib levels measured from 20 patients were comparable with those measured by high-performance liquid chromatography, and there was a strong correlation between the values determined by both methods (Y = 0.976X – 0.207, r = 0.975). As indicated by its specificity and sensitivity, this newly developed ELISA for afatinib is an important tool for TDM and studies of the pharmacokinetics of afatinib.
